FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Study presents an AI-guided approach to target cancer antigens Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected PI3K-Altered CRC HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC MOST POPULAR ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert] July 27, 2020 FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... November 22, 2022 Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed December 9, 2021 What People in Asian American and Pacific Islander Communities Should Know... September 5, 2023 Load more HOT NEWS Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... The Unique Challenges Teenagers and Young Adults With Cancer Face: An... A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and... For Some Kids with Brain Cancer, Targeted Therapy is Better than...
